← All trials
NCT05697055
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 21, 2023
- Primary completion
- May 21, 2023
- Completion date
- Jul 21, 2023
- First posted
- Jan 25, 2023
- Last posted
- Feb 27, 2023
- Enrollment
- 410
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shandong Provincial HospitalLead sponsor
- Gansu Provincial HospitalCollaborator
- People's Hospital of RizhaoCollaborator
- Shandong Provincial HospitalReponsible party - principal investigator
- Southwest Medical UniversityCollaborator
- Shandong first medical UniversityCollaborator
- Shandong Provincial HospitalSponsor investigator
- Shandong Province Qianfoshan HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.